Mezzasalma Advisors LLC Sells 1,774 Shares of Sanofi $SNY

Mezzasalma Advisors LLC trimmed its stake in shares of Sanofi (NASDAQ:SNY) by 14.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,591 shares of the company’s stock after selling 1,774 shares during the period. Mezzasalma Advisors LLC’s holdings in Sanofi were worth $512,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Perigon Wealth Management LLC grew its position in shares of Sanofi by 3.1% during the first quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company’s stock valued at $367,000 after purchasing an additional 201 shares in the last quarter. Capital Analysts LLC boosted its stake in Sanofi by 14.0% during the first quarter. Capital Analysts LLC now owns 1,664 shares of the company’s stock valued at $92,000 after buying an additional 204 shares during the last quarter. Thomasville National Bank boosted its stake in Sanofi by 0.3% during the second quarter. Thomasville National Bank now owns 80,440 shares of the company’s stock valued at $3,886,000 after buying an additional 211 shares during the last quarter. Hexagon Capital Partners LLC grew its holdings in Sanofi by 4.2% during the 1st quarter. Hexagon Capital Partners LLC now owns 5,959 shares of the company’s stock valued at $330,000 after buying an additional 238 shares in the last quarter. Finally, U.S. Capital Wealth Advisors LLC increased its stake in Sanofi by 4.1% in the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 6,227 shares of the company’s stock worth $301,000 after acquiring an additional 247 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors.

Sanofi Trading Up 1.2%

Shares of SNY opened at $50.62 on Friday. The company’s fifty day simple moving average is $48.49 and its 200-day simple moving average is $49.60. The company has a market cap of $124.30 billion, a P/E ratio of 12.17, a P/E/G ratio of 1.23 and a beta of 0.51. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. During the same quarter in the previous year, the company posted $1.73 earnings per share. The business’s revenue for the quarter was down 7.0% on a year-over-year basis. As a group, analysts expect that Sanofi will post 4.36 EPS for the current year.

Analysts Set New Price Targets

SNY has been the subject of a number of research reports. Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $56.00 to $58.00 in a research report on Monday, September 8th. JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Barclays reaffirmed an “overweight” rating on shares of Sanofi in a report on Wednesday, July 2nd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $62.67.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.